What question did this study set out to answer?

To examine the protective effects of melatonin against Adriamycin-induced myocardial toxicity and oxidative damage.

March 6, 2013Experimental and Therapeutic MedicineOpen Access

Protective effect of melatonin against Adriamycin-induced cardiotoxicity

View Full Paper

Ask AI

Bookmark

Why the study?

Does melatonin prevent Adriamycin-induced cardiotoxicity in a rat model of breast cancer?

Population

116 rats with an established breast cancer model

Comparison

Melatonin combined with Adriamycin vs Adriamycin alone, blank control, solvent…

Design

Preclinical, randomly divided

Follow-up

1 month

Authors

YZYan Zhang117th Hospital of People's Liberation Army LLLixin LiSouth China Normal University ZMZhiqian MaFirst Hospital of Shijiazhuang

Discussion

Member takes

Implication

May reduce Adriamycin cardiotoxicity in rats; leaves open translation to human breast cancer therapy.

Key Points

To examine the protective effects of melatonin against Adriamycin-induced myocardial toxicity and oxidative damage.
Randomly allocated 116 breast cancer model rats into five experimental groups: blank, solvent vehicle, Adriamycin (ADM), melatonin (MLT), and melatonin combined with Adriamycin (M+A).
Quantified concentrations of lipid peroxide (LPO), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) in harvested myocardial tissue.
Evaluated myocardial structural alterations via light and electron microscopy, and tracked 1-month overall survival rates across all groups.
ADM administration elevated LPO and significantly suppressed SOD and GSH-Px concentrations relative to the blank control group.
Coadministration of melatonin (M+A group) significantly decreased LPO levels (P<0.05) and significantly increased SOD and GSH-Px levels (P<0.05) compared with the ADM group alone.
Microscopic examination demonstrated substantially attenuated myocardial injury in the M+A group compared to the ADM group, alongside an increased 1-month survival rate.

Structured PICO

Does melatonin prevent Adriamycin-induced cardiotoxicity in a rat model of breast cancer?

Population

116 rats with an established breast cancer model

Intervention

Melatonin combined with Adriamycin

Comparator

Adriamycin alone, blank control, solvent control, and melatonin alone

Outcome

Concentrations of lipid peroxide (LPO), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) in myocardial tissues, myocardial tissue changes (via light and electron microscopy), and 1-month survival ratesurrogate

Melatonin demonstrates a protective role against Adriamycin-induced myocardial oxidative damage and improves survival in a rat model of breast cancer.

Cite This Study

Zhang et al. (2013) studied this question.

synapsesocial.com/papers/6a8255ab24df062650b4b4f2 https://doi.org/10.3892/etm.2013.989

View Full Paper

Ask AI

Bookmark

Protective effect of melatonin against Adriamycin-induced cardiotoxicity

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Protective effect of melatonin against Adriamycin-induced cardiotoxicity

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Also Consider